We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Evotec AG has announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.

Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: “We are particularly pleased about achieving this milestone in the oncology programme, as the alliance was only expanded to this therapeutic area in late 2009. We are very proud of the high value we continue to bring to Boehringer Ingelheim’s research efforts and the ongoing fruitful relationship between the research teams from both companies.”